O-2545

O-2545
Legal status
Legal status
  • In general: unscheduled
Identifiers
  • (6aR,10aR)-6a,7,10,10a-Tetrahydro-3-[5-(1H-imidazol-1-yl)-1,1-dimethylpentyl]-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol
CAS Number
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC26H36N2O2
Molar mass408.586 g·mol−1
3D model (JSmol)
  • CC1=CC[C@H]2[C@@](Oc3c(c(cc(c3)C(CCCCn4cncc4)(C)C)O)[C@@H]2C1)(C)C
  • InChI=1S/C26H36N2O2/c1-18-8-9-21-20(14-18)24-22(29)15-19(16-23(24)30-26(21,4)5)25(2,3)10-6-7-12-28-13-11-27-17-28/h8,11,13,15-17,20-21,29H,6-7,9-10,12,14H2,1-5H3/t20-,21-/m1/s1 ☒N
  • Key:RZGSWWCABDVBGX-NHCUHLMSSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

O-2545 is an analgesic cannabinoid derivative created by Organix Inc. for use in scientific research. Unlike most cannabinoids discovered to date, it is water-soluble, which gives it considerable advantages over many related cannabinoids. It has high affinity for both CB1 and CB2 receptors, with Ki values of 1.5 nM at CB1 and 0.32 nM at CB2.[1]

See also

[edit]

References

[edit]
  1. ^ Martin BR, Wiley JL, Beletskaya I, Sim-Selley LJ, Smith FL, Dewey WL, Cottney J, Adams J, Baker J, Hill D, Saha B, Zerkowski J, Mahadevan A, Razdan RK (September 2006). "Pharmacological characterization of novel water-soluble cannabinoids". The Journal of Pharmacology and Experimental Therapeutics. 318 (3): 1230–9. doi:10.1124/jpet.106.104109. PMID 16757541. S2CID 14864925.